A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD
The purpose of this webinar is to provide an overview of a new clinical study for people living with ALS and a mutation in the C9orf72 gene. We will describe the scientific rationale for the study, the investigational drug (TPN-101), eligibility criteria, and what study participation involves. This webinar will also share contact information for interested individuals to learn more about study participation. This webinar will be held live on Friday, May 6th from 10:30-11:30 AM EDT.